Screening of congenital developmental defects

Search for pregnant women at significant risk for a specific pathology that may adversely affect fetal development. Screening methods focus on early detection of chromosomal aberrations and other morphological or functional abnormalities of the fetus. They also focus on the detection of diseases that are high risk for the physiological development of the fetus (infections, diabetes, pre-eclampsia).

In case of a positive screening finding, a diagnostic examination is indicated to confirm the diagnosis.

Screening in the 1st trimester
Comprehensive prenatal screening (up to 14 weeks of gestation) Early detection of the most common fetal morphological and chromosomal birth defects. The preferred method is the so-called combined test (biochemical and ultrasound), which unfortunately is not covered by health insurance.

Laboratory examination (up to the 14th week)
Determination of blood count and blood group RhD', screening for irregular anti-erythrocyte antibodies and serology for HIV, HBsAg' and antibodies to syphilis.

As part of the screening for diabetes in pregnancy, we determine fasting glycaemia. If the values are elevated (>5.1 mmol/l), we repeat the test on another day. Values (5.1-6.9 mmol/l) correspond to gestational diabetes, (above 7 mmol/l) we speak of overt DM. Regardless of the type of disease, hyperglycaemia values must be strictly corrected and stabilised to values within the physiological range (hyperglycaemia is a likely cause of a pathogenic effect on fetal development).

UZ examination (up to 14 weeks)
Determination of the fetal count; in multiple fetuses, we also determine the number of placentas (chorionicity) and amniotic envelopes (amnionicity). Assess fetal vitality and measure the craniocervical distance (CRL). We compare the value with the population standard to determine the gestational age of the fetus and calculate the expected date of delivery.''

Combined test (patient reimbursement)
A test with high detection' of all fetal birth defects (80%).

It takes into account blood marker values, ultrasound scan data and medical history (age, weight, height, risk factors in family and personal history, course of previous pregnancy, etc.). In addition to the risk of chromosomal defects, today's methods allow the risk of pre-eclampsia, fetal growth restriction and premature birth to be determined.

In addition, the gestational age of the fetus can be determined, multiple pregnancies can be detected, fetal anatomy, amniotic fluid quantity and placental localization can be completely evaluated.


 * 1) Blood collection (11+0 to 11+6)' - determination of PAPP-A, free-βhCG and PlGF levels.
 * 2) Ultrasound scan (11+0 to 13+6) - measure CRL, clarify gestational age, presence of nasal os, measure NT (nuchal translucency), tricuspid regurgitation, flow in ductus venosus and measure flow in both aa. uterinae.

When screening positive for chromosomal aberrations in the first trimester, we indicate chorionic villus sampling or amniocentesis. If the risk of pre-eclampsia and growth restriction is positive, we administer 1x daily ASA as a prophylactic until 36 weeks.

Non-invasive prenatal diagnosis (patient reimbursement)
Can be determined after the 10th week of pregnancy. Karyotype is constructed from free non-cellular fetal DNA in maternal plasma. It allows screening for aneuploidies (Down's, Edwards, Patau syndrome), other numerical aberrations of chromosomes and gonosomal abnormalities. It also allows the determination of fetal sex and RhD'.

It is a suitable alternative to invasive testing, with a very high detection rate. The disadvantage is that positive detections must be confirmed diagnostically by invasive methods. This is a relatively expensive test that is not covered by insurance.

2nd trimester screening
We perform regular ultrasound examinations 'at 20-22 weeks. We can offer patients a detailed morphological evaluation, but this is not covered by insurance.

UZ examination (week 20-22)
We evaluate the number of fetuses, vitality, placental localization, amount of amniotic fluid. Biometry includes measurements of biparietal dimension (BPD), head circumference (HC), abdominal circumference (AC), and femur length (FL). From these values, we can estimate the approximate fetal weight (EFW). We then assess the morphology of tissues and organs, looking for anomalies.

Detailed morphological ultrasound examination (paid by the patient)
Compared to the classical ultrasound, we also perform a detailed examination of all organs. We assess their morphology in relation to gestational age and focus on typical signs of morphological defects. We record the results in a protocol.

oGTT (24th-28th week)
Undergoes all women with a negative first trimester uptake. Performed in the morning, after 8 hours of fasting (3 days before the test classic eating habits). On fasting, we draw blood from a peripheral vein and determine the current glycemic level. The woman then drinks a solution of 75 g glucose in 300 ml water (within 3-5 minutes). Another blood draw is performed after the 60th (Gly < 10.0 mmol/l) and after the 120th minute (Gly < 8.5 mmol/l). If there is no fall in glycemia to baseline even after 120 minutes, the patient is referred to the care of a diabetologist.

Screening in the 3rd trimester
In 10% of pregnancies there is fetal growth retardation from the second half onwards (about 7%) we also find a failure of placental function, leading to inadequate transfer of nutrients and oxygen (hypoxic newborn).

Laboratory examination (28-34 weeks)
Determination of blood count' and serology for syphilis'

UZ examination (30th-32nd week)
Assess the number of fetuses, their vitality and position. We determine biometry: by measuring BPD, HC, AC, FL, and then calculating EFW. Examination of organ morphology. Assess placental localization (consider the distance of the lower pole from the internal gate) and the amount of amniotic fluid.

Vaginorectal GBS detection (week 35-37)
Streptococcus agalactiae (type B) is found in 30% of women as a natural part of the vaginal microflora. However, it is the most common life-threatening disease of newborns (mortality rate 20-30%). Infection of the newborn occurs during passage through the birth canal. Risk factors include prematurity, premature amniotic fluid, low gestational age, fever during labour, etc. Early infections (80%) present with neonatal sepsis. Late ones more often present as meningitis.

In case of positive detection, we indicate ATB screen at delivery (i.v. penicillin).

Screening for fetal growth restriction (patient reimbursement)
Performed at 36 weeks. Growth restriction occurs in 5-10% of pregnancies and is the cause of 30-50% of intrauterine deaths. The main aim of this examination is to check the growth of the fetus and its adequate vascular supply.

We perform biometry of the fetus (determination of size and weight). Determine the Doppler flow parameters by measuring the pulsatility index (a. cerebri media, a. umbilicalis, ductus venosus and aa. uterinae). We then generate a biophysical profile of the fetus. This will provide us with information on possible risks. A na základě toho můžeme plánovat další postup (včetně předčasného ukončení těhotenství).

Další postupy ve 3. trimestru

 * Od 28. týdne: možné provést antepartální RhD aloimunizaci u Rh- matek.
 * 36.-37. týden: evidence těhotné ženy do porodnice.
 * Od 38. týdne: ženám nabídnuta možnost indukce porodu pomocí Hamiltonova hmatu.
 * Od 40. týdne: podle zvážení lékaře provádíme kardiotokografický non-stress test (posouzení hemodynamické stability plodu v klidovém stavu).
 * Mezi 41+0 a 42+0: se podnikají kroky k ukončení těhotenství (preindukce, indukce vaginálního porodu).

Související články

 * Prenatální diagnostika
 * Vrozené vývojové vady
 * Indikace chromozomálního vyšetření
 * Preeklampsie
 * Růstová restrikce plodu